+

WO2013012811A2 - Modulation immunothérapeutique de maladie amyloïdogène à l'aide de protéines et peptides polymérisés non fibrillogènes, non amyloïdogènes - Google Patents

Modulation immunothérapeutique de maladie amyloïdogène à l'aide de protéines et peptides polymérisés non fibrillogènes, non amyloïdogènes Download PDF

Info

Publication number
WO2013012811A2
WO2013012811A2 PCT/US2012/046941 US2012046941W WO2013012811A2 WO 2013012811 A2 WO2013012811 A2 WO 2013012811A2 US 2012046941 W US2012046941 W US 2012046941W WO 2013012811 A2 WO2013012811 A2 WO 2013012811A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
protein
amino acid
seq
polymerized product
Prior art date
Application number
PCT/US2012/046941
Other languages
English (en)
Other versions
WO2013012811A3 (fr
Inventor
Thomas M. Wisniewski
Fernando Goni
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Publication of WO2013012811A2 publication Critical patent/WO2013012811A2/fr
Publication of WO2013012811A3 publication Critical patent/WO2013012811A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Definitions

  • the present invention relates to pharmaceutical agents and antibodies suitable for the diagnosis, prevention, and treatment of amyloid disease.
  • Amyloidosis broadly encompasses a variety of diseases that are characterized by the extracellular or intracellular deposition of amyloid proteins in tissues and/or organs. Amyloids are insoluble fibrous protein/peptide aggregates and their deposition may occur in localized sites or systemically. The fibrillar composition of these deposits is an identifying characteristic for the various forms of amyloid disease. In some cases the amyloid protein/peptide accumulates
  • intracellular amyloid proteins include cc-synuclein, forming Lewy bodies in
  • AD Alzheimer's disease
  • ⁇ amyloid- ⁇
  • Intracerebral and cerebrovascular deposits composed primarily of fibrils of the pathological ⁇ peptide are characteristic of both familial and sporadic forms of AD.
  • abnormally folded and phosphorylated tau protein forms toxic oligomeric structures and neurofibrillary tangles in AD.
  • prion-associated diseases such as Creutzfeld-Jacob disease
  • Creutzfeld-Jacob disease have also been characterized as amyloid diseases.
  • the pathogenesis of prion disease is linked to a change of the cellular prion protein (PrP c ) into the disease associated PrP c (Sc for scrapie).
  • PrP c cellular prion protein
  • the present invention is directed to overcoming these and other deficiencies in the art.
  • a first aspect of the present invention relates to a non-amyloidogenic, non-fibrillogenic polymerized product comprising two or more protein and/or peptide units, where each unit is independently selected from the group consisting of an amyloid-beta ( ⁇ ) peptide, an a-synuclein protein or peptide, a tau protein or peptide, a TAR DNA-binding protein 43 (TDP-43) protein or peptide, an amylin protein or peptide, a prion protein (PrP) protein or peptide, and any combination thereof,
  • a second aspect of the present invention is directed to an isolated antibody or binding portion thereof having antigenic specificity for an epitope a non- amyloidogenic, non-fibrillogenic polymerized product.
  • the polymerized product comprises two or more protein and/or peptide units, each unit independently selected from the group consisting of an amyloid-beta ( ⁇ ) peptide, an a-synuclein protein or peptide, a tau protein or peptide, a TAR DNA-binding protein 43 (TDP-43) protein or peptide, an amylin protein or peptide, a prion protein (PrP) protein or peptide, and any combination thereof.
  • ⁇ amyloid-beta
  • TrP TAR DNA-binding protein 43
  • the development of an effective immunotherapeutic approach for the prevention and treatment of amyloid related diseases has been hindered by potential cell-mediated toxicity, non-specific immunological targeting of both normal and amyloidogenic proteins, and overall poor efficacy.
  • the immunotherapeutic approach of the present invention employs non-amyloidogenic, non-fibrillogenic polymerized protein and/or peptides and co-polymerized proteins and/or peptides to generate a specific immunological response to conformational epitopes that are shared by various amyloidogenic proteins, thereby overcoming many of the above noted obstacles.
  • Figures 1 A- ID show the results of locomotor activity testing in SwDI transgenic (Tg) control mice and Tg mice vaccinated with synthetic polymerized ⁇ peptide ( ⁇ 1-30 ⁇ 8 ⁇ 9 ⁇ ), polymerized ABri peptide (ABri-Glut), or polymerized ⁇ 1-42 peptide. No significant differences between the groups were noted in distance traveled ( Figure 1 A) or mean velocity (Vrnean) ( Figure 1 C).
  • Figures 2A-2D show the results of locomotor activity testing in Tg3x transgenic control mice and Tg mice vaccinated with synthetic polymerized ⁇ peptide ( ⁇ 1-30 ⁇ 8 ⁇ 9), polymerized ABri peptide (ABri-Glut), or the combination of ⁇ 1-30 Ki gKi 9 and ABri polymerized peptides. No significant differences between the groups were noted in distance traveled ( Figure 2 A), maximum velocity (Vmax) ( Figure 2B), mean velocity (Vmean) ( Figure 2C), or in resting time (Figure 2D).
  • Figures 3A-3C illustrate the effects of polymerized peptide vaccination on behavioral improvement in 3xTg and SwDI transgenic animal models of amyloidogenic disease.
  • Figure 3A is a graph depicting the results of the radial arm maze. The number of errors (y-axis) versus the day of testing (x-axis) are plotted for 3xTg mice vaccinated with polymerized ABri, transgenic control (Tg control), and wildtype. Vaccinated transgenic animals commit significantly fewer errors that non- treated transgenic and perform similarly to the wildtype animals.
  • Figure 3C is another graph depicting the results of the radial arm maze cognitive testing.
  • Figures 4A-4C are bar graphs showing IgM and IgG antibody levels raised in TgSwDI mice vaccinated with polymerized ABri peptide (pABri) ( Figure 4A), polymerized ⁇ 1 -30 ⁇ 8 ⁇ 9 ( Figure 4B), and polymerized ⁇ 1-42 peptide ( Figure 4C).
  • Antibody titers against ⁇ 1-40, ⁇ 1-42, pABri, and a mutant ⁇ ⁇ - 30KK were measured in vaccinated mice prior to the first inoculation (TO), after the 6th inoculation (Tl ) and at the time of sacrifice (TF).
  • TO first inoculation
  • Tl 6th inoculation
  • TF time of sacrifice
  • Figures 5A-5D are bar graphs showing IgM and IgG antibody levels raised in 3xTg mice vaccinated with polymerized ABri peptide (Figure 5A), polymerized ⁇ 1 -30 18 Ki9 ( Figure 5B), the combination of polymerized peptides (Figure 5C), and vehicle ( Figure 5D).
  • Antibody titers against ⁇ 1-40, ⁇ 1-42, pABri, and a mutant ⁇ 1-30 ⁇ were measured in vaccinated mice prior to the first inoculation (TO), after the 6th inoculation (Tl ), and at the time of sacrifice (TF).
  • TO first inoculation
  • Tl 6th inoculation
  • TF time of sacrifice
  • Figures 6A-6C depict the amyloid and paired helical fiber (PHFl) burden in Tg3x transgenic control and vaccinated animals.
  • Figures 6B and 6C show a reduction in PHFl in the hippocampus and cortex, respectively, of Tg3x animals administered polymerized ABri or the combination of polymerized ABri and ⁇ 1-30 ⁇ 8 ⁇ 9 ⁇ (p ⁇ 0.0001 one way ANOVA post hoc; p ⁇ 0.001 Tg-ABri and Tg-combined vs. Tg-control and Tg- ⁇ - 30I 8 KIQK for both hippocampal and cortical analyses). No significant difference was found between Tg-control and Tg- ⁇ 1-30 ⁇ 8 ⁇ 9 ⁇ treated animals.
  • Figures 7A-7B depict the amyloid burden in SwDI transgenic control and vaccinated animals.
  • Figure 7A is a bar graph showing the reduction in hippocampal amyloid burden in polymerized ABri vaccinated (Tg pABri), polymerized ⁇ 1-30 ⁇ 8 ⁇ 19 ⁇ vaccinated (Tg- ⁇ 1 -30KK), and polymerized ⁇ 1-42 vaccinated (Tg-Ap42) animals compared to transgenic control (Tg Control).
  • Figure 7B is an electron micrograph (EM) image of negatively stained polymerized ⁇ 1 -42 peptide, which is predominately in the form of spherical particles of ⁇ 200nm.
  • EM electron micrograph
  • Figures 8A-8B are EM images of aged ⁇ 1 -42 peptides.
  • Figure 8 A ⁇ -42 peptide was aged for 3 months after controlled polymerized with
  • Figure 8B is an ⁇ 1 -42 peptide from the same synthesis batch as the peptide in Figure 8A, This peptide was dissolved in saline and aged for 3 months before the EM. In contrast to the polymerized ⁇ 1 -42 peptide, the unpolymerized ⁇ 1 -42 sample was completely fibrillized.
  • Figure 9 shows specific anti-PrP IgA antibodies in feces of control and deer vaccinated with prion protein (PrP) as measured by ELISA.
  • White tail deer were orally inoculated with an attenuated salmonella carrying deer-PrP or an empty vector (control) four times over a period of a few months following the protocol for mucosal vaccination described in Goni et al, "High Titers of Mucosal and Systemic Anti-PrP Antibodies Abrogate Oral Prion Infection in Mucosal-Vaccinated Mice," Neurosci. 153:679-686 (2008), which is hereby incorporated by reference in its entirety.
  • Antibody titers were measure before the first inoculation (TO), after the fourth inoculation (T5), and ten days after the boost (T6).
  • the boost with PrP and polymerized PrP fragments was repeated two months after the first boost, and titers were again measured 10 days after the second boost (T7).
  • the control group did not develop any noticeable titer whereas the vaccinated group showed some increase in mucosa titer after the immune response was established with the salmonella oral delivery.
  • the titers were very low (T5) but were greatly enhanced after the animals were boosted with the polymerized PrP and PrP fragments (T6 and T7) showing the importance of these antigenic preparation to have a sustainable immune response.
  • Figure 1 1 shows immunoblots of salmonella lysate (lane 1), sheep PrP
  • Figure 12 is a Kaplan and Meier survival curve showing the protective effect of PrP vaccination in White Tail Deer at 18 months after challenge. Three out of six control animals became sick with the prionoses Chronic Wasting Disease and were properly euthanized. None of the vaccinated animals had signs of the disease at 18-months. Protection for the progression of the disease is evident and due to the immune response elicited by the inoculations involving the polymerized PrP and PrP fragments.
  • a first aspect of the present invention relates to a non-amyloidogenic, non-fibril logenic polymerized product comprising two or more protein and/or peptide units, where each unit is independently selected from the group consisting of an amyloid-beta ( ⁇ ) peptide, an a-synuclein protein or peptide, a tau peptide or peptide, a TAR DNA-binding protein 43 (TDP-43) protein or peptide, an amylin protein or peptide, a PrP protein or peptide, and any combination thereof.
  • ⁇ amyloid-beta
  • TDP-43 TAR DNA-binding protein 43
  • suitable ⁇ peptides of the polymerized product include, without limitation, ⁇ 1-42 and peptides derived therefrom.
  • the amino acid sequence of ⁇ 1-42 is provided as SEQ ID NO: 1 below. daefrhdsgy evhhqklvff aedvgsnkga iiglmvggw ia (SEQ ID NO:l)
  • the ⁇ peptide of the polymerized product comprises amino acid residues 1-42 of SEQ ID NO: 1.
  • suitable ⁇ peptides of the polymerized product include, without limitation, peptides comprising amino acid residues 1-16 of SEQ ID NO: l , amino acid residues 1-20 of SEQ ID NO: 1. amino acid residues 1-30 of SEQ ID NO: 1 , amino acid residues 1 -40 of SEQ ID NO: 1, amino acid residues 1-42 of SEQ ID NO: l , amino acid residues 10-30 of SEQ ID NO: l , amino acid residues 20-40 of SEQ ID NO: 1 , and amino acid residues 20-42 of SEQ ID NO: 1.
  • the ⁇ peptide of the polymerized product contains two amino acid substitutions at amino acid residues 18 and 19 of SEQ ID NO: 1.
  • the amino acid substitutions comprise a valine to lysine substitution at position 18 and a phenylalanine to lysine substitution at position 19 of SEQ ID NO: 1.
  • Peptides having these two amino acid substitutions are referred to as ⁇ ⁇ 8 ⁇ 9 peptides and are derived from the amino acid sequence of SEQ ID NO:2 below. daefrhdsgy evhhqklkkf aedvgsnkga iiglmvggw ia (SEQ ID NO: 2)
  • suitable ⁇ peptides comprising the double lysine substitution include, without limitation, peptides comprising amino acid residues 1 -30 of SEQ ID NO:2 ( ⁇ 1 -30 ⁇ 8 ⁇ 19 ), amino acid residues 1 -40 of SEQ ID NO:2 ( ⁇ ⁇ - 40K i 8 Ki 9 ), amino acid residues 1-42 of SEQ ID NO:2 ( ⁇ 1 -42 ⁇ 8 ⁇ 9 ), amino acid residues 1 -20 of SEQ ID NO:2 ( ⁇ 1-20 ⁇ 18 ⁇ 9 ), amino acid residues 10-30 of SEQ ID NO:2 ( ⁇ 10-30 ⁇ , 8 ⁇ , 9 ), amino acid residues 10-40 of SEQ ID NO:2 ( ⁇ - 40Ki 8 Ki 9 ), amino acid residues 10-42 of SEQ ID NO:2 ( ⁇ 10-42 ⁇ , 8 ⁇ (9 ), amino acid residues 20-40 of SEQ ID NO:2 ( ⁇ 20-40 ⁇ 8 ⁇ (9 ), and amino acid residues 20-42 of SEQ ID NO:2 (
  • the polymerized product of the present invention may comprise a homopolymer of an ⁇ peptide or a copolymer of two or more different ⁇ peptides.
  • the polymerized product of the present invention may comprise a copolymer of an ⁇ protein or peptide co-polymerized with any one or more of an a- synuclein protein or peptide, a tau protein or peptide, a TDP-43 protein or peptide, an amylin protein or peptide, and/or a PrP protein or peptide.
  • the polymerized product comprises a copolymer of one or more ⁇ peptides copolymerized with one or more a-synuclein proteins or peptides. In another embodiment of the present invention, the polymerized product comprises a copolymer of one or more ⁇ peptides copolymerized with one or more tau proteins or peptides. In another embodiment of the present invention, the polymerized product comprises a copolymer of one or more ⁇ peptides copolymerized with one or more TDP-43 proteins or peptides
  • the polymerized product of the present invention may also comprise an a-synuclein protein or peptide thereof.
  • the a-synuclein protein comprises the amino acid sequence of SEQ ID NO:3.
  • the a-synuclein protein of the polymerized product comprises amino acid residues 1-140 of SEQ ID NO:3.
  • Peptides of ⁇ -synuclein derived from the amino acid sequence of SEQ ID NO: 3 are also suitable for use in the polymerized product of the present invention.
  • the peptide comprises at least five contiguous amino acids of SEQ ID NO:3.
  • the peptide comprises at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 90 or at least 100 contiguous amino acids of SEQ ID NO:3.
  • the ⁇ -synuclein peptide is a C- terminal ⁇ -synuclein peptide as disclosed in WO 2004/041067 to Schenk at al., which is hereby incorporated by reference in its entirety.
  • Suitable C-terminal a-synuclein peptides for use in the polymerized product of the present invention include, without limitation, peptides comprising amino acids residues 70- 140 of SEQ ID NO:3, amino acid residues 100- 140 of SEQ ID NO:3, amino acid residues 120- 140 of SEQ ID NO:3, amino acid residues 130- 140 of SEQ ID NO:3, or amino acid residues 135- 140 of SEQ ID NO:3.
  • the polymerized product of the present invention may comprise a homopolymer of an ⁇ -synuclein protein or peptide or a copolymer of two or more different ⁇ -synuclein proteins or peptides.
  • the polymerized product of the present invention may comprise a copolymer of an ⁇ -synuclein protein or peptide co-polymerized with any one or more of an ⁇ peptide, a tau protein or peptide, a TDP-43 protein or peptide, an amylin protein or peptide, and/or a PrP protein or peptide.
  • the pharmaceutical composition of the present invention may also comprise a tau protein or peptide thereof.
  • Suitable tau proteins of the present invention include any of the eight isoforms of the human tau protein that are known in the art (see NCBI Accession Nos. NP_058519.3, NP_005901 , NP_058518.1 , NP_058525.1, NP_001 1 16539.1 , NP_001 1 16538.2, NP_001 190180.1 , and
  • the tau isoforms vary in the number of N-terminal inserts resulting from the splicing of exons two and three, and microtubule-binding domains resulting from the splicing of exon ten.
  • the amino acid sequence corresponding to human tau protein isoform 2 (441a.a), containing two N-terminal inserts and four microtubule binding (2N4R) domains is provided as SEQ ID NO:4 below. Met Ala Glu Pro Arg Gin Glu Phe Glu Val Met Glu Asp His Ala Gly 1 5 10 15
  • Lys Ser Lys lie Gly Ser Thr Glu Asn Leu Lys His Gin Pro Gly Gly
  • Gly Lys Val Gin lie lie asn Lys Lys Leu Asp Leu Ser Asn Val Gin
  • Lys lie Gly Ser Leu Asp Asn lie Thr His Val Pro Gly Gly Gly Asn
  • a tau protein of the polymerized product of the present invention comprises amino acid residues 1-441 of SEQ ID NO:4.
  • the composition of the invention comprises amino acid residues 1-758 of tau isoform 1 (NP_058519.3), amino acid residues 1-383 of tau isoform 3 (NP_058518.1 ), amino acid residues 1 -352 of tau isoform 4 (NP_058525.1), amino acid residues 1 -412 of tau isoform 5 (NP_001 1 16539.1 ), amino acid residue 1-776 of tau isoform 6 (NP_001 1 16538.2), amino acid residues 1 -381 of tau isoform 7 (NP_001 190180.1 ), and amino acid residues 1 -410 of tau isoform 8
  • the pharmaceutical composition of the present invention may also comprise tau peptides derived from the amino acid sequence of SEQ ID NO:4 or the amino acid sequence of any other tau isoform.
  • the tau peptide comprises at least five contiguous amino acids of a tau protein, e.g., the tau protein of SEQ ID NO:4.
  • the tau peptide comprises at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 90, or at least 100 contiguous amino acids of a tau protein, e.g., the tau protein of SEQ ID NO:4.
  • the peptide comprises at least 200, at least 300, at least 400, or at least 500 contiguous amino acids, of a tau protein.
  • tau peptides that are suitable for polymerization and incorporation into the polymerized product of the present invention are disclosed in U.S. Patent No. 8,012,936 to NASAdsson et al., which is hereby incorporated by reference in its entirety.
  • Suitable peptides include, without limitation, amino acid residues 1-30 of SEQ ID NO:4, amino acid residues 30-60 of SEQ ID NO:4, amino acid residues 60-90 of SEQ ID NO:4, amino acid residues 90-120 of SEQ ID NO:4, amino acid residues 120-150 of SEQ ID NO:4, amino acid residues 150-180 of SEQ ID NO:4, amino acid residues 210-240 of SEQ ID NO:4, amino acid residues 270- 300 of SEQ ID NO:4, amino acid residues 300-330 of SEQ ID NO:4, amino acid residues 330-360 of SEQ ID NO:4, amino acid residues 360-390 of SEQ ID NO:4, amino acid residues 390-420 of SEQ ID NO:4, amino acid residues 41 1-440 of SEQ ID NO 4, amino acid residues 133-162 of SEQ ID N04, amino acid residues 379- 409 of SEQ ID N04, amino acid residues 192-221 of SEQ ID NO:4, amino acid residues 221-250 of SEQ ID N04, or amino
  • the polymerized product of the present invention may comprise a homopolymer of tau protein or peptide or a copolymer of two or more different tau proteins or peptides.
  • the polymerized product of the present invention may comprise a copolymer of a tau protein or peptide co-polymerized with any one or more of an ⁇ peptide, an -synuclein protein or peptide, a TDP43 protein or peptide, an amylin protein or peptide, and/or a PrP protein or peptide.
  • the polymerized product of the present invention may also comprise a
  • TDP 43 TAR DNA-binding protein 43 (TDP 43) or peptide thereof.
  • the human TDP 43 protein comprises the amino acid sequence of SEQ ID NO:5.
  • the TDP-43 protein of the polymerized product comprises amino acid residues 1-414 of SEQ ID NO:5.
  • Peptides of TDP-43 derived from the amino acid sequence of SEQ ID NO:5 are also suitable for use in the pharmaceutical composition of the present invention.
  • the TDP-43 peptide comprises at least five contiguous amino acids of SEQ ID NO:5.
  • the TDP-43 peptide comprises at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, or at least 300 contiguous amino acids of SEQ ID NO:5.
  • the polymerized product of the present invention may comprise a homopolymer of a TDP-43 protein or peptide or a copolymer of two or more different TDP-43 proteins or peptides.
  • the polymerized product of the present invention may comprise a copolymer of a TDP-43 protein or peptide co-polymerized with any one or more of an ⁇ peptide, a tau protein or peptide, an a-synuclein protein or peptide, an amylin protein or peptide, and/or a PrP protein or peptide.
  • the polymerized product of the present invention can also comprise an amylin protein or peptide thereof.
  • the human amylin protein comprises the amino acid sequence of SEQ ID NO:6. 1 hq ekrkcnt atcatqrlan flvhssnnfg ailsstnvgs ntygkrnave vlkreplnyl 61 pi (SEQ ID NO: 6)
  • the amylin protein of the polymerized product comprises amino acid residues 1-62 of SEQ ID NO:6.
  • Peptides of amylin derived from the amino acid sequence of SEQ ID NO:6 are also suitable for use in the pharmaceutical composition of the present invention.
  • the amylin peptide comprises at least five contiguous amino acids of SEQ ID NO:6.
  • the amylin peptide comprises at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60 contiguous amino acids of SEQ ID NO:6.
  • the polymerized product of the present invention may comprise a homopolymer of an amylin protein or peptide or a copolymer of two or more different amylin proteins or peptides.
  • the polymerized product of the present invention may comprise a copolymer of an amylin protein or peptide co-polymerized with any one or more of an ⁇ peptide, a tau protein or peptide, an a-synuclein protein or peptide, a TDP-43 protein or peptide, and/or a PrP protein or peptide.
  • the polymerized product of the present invention may also comprise a prion protein or peptide thereof.
  • the human prion protein comprises the amino acid sequence of SEQ ID NO: 7. 1 manlgcwmlv lfvatwsdlg lckkrpkpgg ntggsrypg qgspggnryp pqggggwgqp 61 gggwgqphg ggwgqp gggqp ggg wgqphgggwg qgggthsqwn kpskpktnmk hmagaaaaga 121 wgglggyvl gsamsrpiih fgsdyedryy renmhrypnq vyyrpmdeys nqnnfvhdcv 181 nitikqhtvt ttkgenfte tdvkmmerw eqmcitqyer esqa
  • the prion protein of the polymerized product comprises amino acid residues 1-253 of SEQ ID NO:7 or analogs thereof.
  • Peptides of prion protein derived from the amino acid sequence of SEQ ID NO:7 are also suitable for use in the polymerized product of the present invention.
  • the peptide comprises at least five contiguous amino acids of SEQ ID NO:7.
  • the peptide comprises at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 90 or at least 100, at least 125, and least 150, at least 200, or at least 225 contiguous amino acids of SEQ ID NO:7.
  • the polymerized product of the present invention may comprise a homopolymer of an PrP protein or peptide or a copolymer of two or more different PrP proteins or peptides.
  • the polymerized product of the present invention may comprise a copolymer of an PrP protein or peptide co-polymerized with any one or more of an ⁇ peptide, a tau protein or peptide, an a-synuclein protein or peptide, a TDP-43 protein or peptide, and/or an amylin protein or peptide as described herein.
  • the polymerized product of the present invention may further comprise one or more polymerized ABri peptides (CSRTVKKNIIEEN; SEQ ID NO: 8), ADan peptides (CFNLFLNSQEKHY; SEQ ID NO:9), or ABri/ADan fusion peptides (CSRTVKKNIIEENGSGSGCFNLFLNSQEKHY; SEQ ID NO: 10) as disclosed in U.S. Patent Application Publication No. 20100284909 to Wisniewski et al., which is hereby incorporated by reference in its entirety.
  • the proteins and peptides of the polymerized product of the present invention may comprise naturally occurring peptides or analog peptides.
  • Analog peptides typically differ from naturally occurring peptides at one, two, or a few positions, often by virtue of conservative substitutions.
  • Analogs typically exhibit at least 80 or 90% sequence identity with natural peptides.
  • Some analogs include unnatural amino acids or modifications of N or C terminal amino acids at one, two or a few positions.
  • unnatural amino acids are D-amino acids, alpha amino acids, alpha-disubstituted amino acids, N-alkyl amino acids, lactic acid, 4- hydroxyproline, gamma-carboxyglutamate, epsilon-N,N,N-trimethyllysine, epsilon- N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3- methylhistidine, 5-hydroxylysine, omega-N-methylarginine, ⁇ -alanine, ornithine, norleucine, norvaline, hydroxproline, thyroxine, gamma-amino butyric acid, homoserine, citrulline, and isoaspartic acid.
  • Analog peptides can be screened for prophylactic or therapeutic efficacy using animal models as described in the
  • the polymerized product comprises a polymer of a fusion peptide.
  • Suitable fusion peptides contain any first ⁇ , ⁇ -synuclein, tau, TDP-43, amylin, or prion protein peptide of the present invention fused to any second ⁇ , ⁇ -synuclein, tau, TDP-43, amylin, or prion protein peptide of the present invention.
  • the fusion peptide preferably contains a short linker sequence coupling the first peptide to a second peptide.
  • Preferred linker sequences include glycine-rich (e.g. G3.5) or serine-rich (e.g. GSG, GSGS, GSGSG, GS N G) linker sequences.
  • the polymerized product may contain a polymer or copolymer of any one or more of the ⁇ , ⁇ - synuclein, tau, TDP-43, amylin, or prion protein proteins or peptides described herein further linked in-frame to an adjuvant polypeptide.
  • the adjuvant polypeptide can be any adjuvant polypeptide known in the art, including, but not limited to, cholera toxin B, flagellin, human papillomavirus LI or L2 protein, herpes simplex glycoprotein D (gD), complement C4 binding protein, TL4 ligand, and IL- 1 ⁇ .
  • the protein or peptides comprising the polymers of the polymerized product of the present invention may be linked directly to the adjuvant polypeptide or coupled to the adjuvant by way of a short linker sequence.
  • Suitable linker sequences include glycine or serine-rich linkers described supra or other flexible immunoglobulin linkers as disclosed in U.S. Patent No. 5,516,637 to Huang et al, which is hereby incorporated by reference in its entirety.
  • the polymerized product of the present invention may contain a polymer or copolymer of any one of the ⁇ , ⁇ -synuclein, tau, TDP-43, amylin, or prion protein proteins or peptides described supra conjugated to an immunogenic carrier molecule.
  • the immunogenic carrier molecule can be covalently or non-covalently bonded to the proteins or peptides as described herein.
  • Suitable immunogenic carrier molecules include, but are not limited to, serum albumins, chicken egg ovalbumin, keyhole limpet hemocyanin, tetanus toxoid, thyroglobulin, pneumococcal capsular polysaccharides, CRM 197, immunoglobulin molecules, alum, and meningococcal outer membrane proteins.
  • T-cell epitopes such as tetanus toxoid (e.g., the P2 and P30 epitopes), Hepatitis B surface antigen, pertussis, toxoid, diphtheria toxoid, measles virus F protein, Chlamydia trachomatis major outer membrane protein, Plasmodium falciparum circumsporozite T, P. falciparum CS antigen, Schistosoma mansoni triose phosphate isomersae, Escherichia coli TraT, and Influenza virus hemagluttinin (HA).
  • T-cell epitopes such as tetanus toxoid (e.g., the P2 and P30 epitopes), Hepatitis B surface antigen, pertussis, toxoid, diphtheria toxoid, measles virus F protein, Chlamydia trachomatis major outer membrane protein,
  • T helper cell epitopes which are derived from hepatitis B virus, Bordetella pertussis, Clostridium tetani, Pertusaria trachythallina, E. coli, Chlamydia trachomatis, Diphtheria, P. falciparum, and Schistosoma mansoni ⁇ see U.S. Patent No. 6,906, 169 to Wang; U.S. Patent Application Publication No. 20030068325 to Wang, and WO 2002/096350 to Wang, which are hereby incorporated by reference in their entirety).
  • the peptides and proteins of the present invention can be linked to immunogenic carrier molecules by chemical crosslinking prior to polymerization.
  • Techniques for linking a peptide immunogen to an immunogenic carrier molecule include the formation of disulfide linkages using N-succinimidyl-3-(2-pyridyl-thio) propionate (SPDP) and succinimidyl 4-(N-maleimidomethyl)cyclohexane- l - carboxylate (SMCC) (if the peptide lacks a sulfhydryl group, this can be provided by addition of a cysteine residue).
  • SPDP N-succinimidyl-3-(2-pyridyl-thio) propionate
  • SMCC succinimidyl 4-(N-maleimidomethyl)cyclohexane- l - carboxylate
  • the one or more proteins or peptides comprising the polymers or copolymers of the polymerized product of the present invention can be synthesized by solid phase or solution phase peptide synthesis, recombinant expression, or can be obtained from natural sources.
  • Automatic peptide synthesizers are commercially available from numerous suppliers, such as Applied Biosystems, Foster City,
  • Recombinantly expressed peptides can be purified using any one of several methods readily known in the art, including ion exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, gel filtration, and reverse phase chromatography.
  • the peptide is preferably produced in purified form (preferably at least about 80% or 85% pure, more preferably at least about 90% or 95% pure) by conventional techniques.
  • purified form preferably at least about 80% or 85% pure, more preferably at least about 90% or 95% pure
  • the peptide can be isolated and purified by centrifugation (to separate cellular components from supernatant containing the secreted peptide) followed by sequential ammonium sulfate precipitation of the supernatant.
  • the fraction containing the peptide is subjected to gel filtration in an appropriately sized dextran or polyacrylamide column to separate the peptides from other proteins. If necessary, the peptide fraction may be further purified by HPLC.
  • Polymerization of the proteins or peptides alone or conjugated to an adjuvant polypeptide or immunogenic earner molecule can be achieved using standard techniques known in the art.
  • polymerization refers to process of reacting two or more peptide and/or protein units together under suitable conditions to form three-dimensional networks or polymer chains.
  • the proteins and peptides can be polymerized by a reaction with a cross linking reagent.
  • Suitable cross-linking reagents include, but are not limited to glutaraldehyde and l -Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) (see Goni et al., "Immunomodulation Targeting Abnormal Protein Conformation Reduced Pathology in a Mouse Model of Alzheimer's Disease," PLoS One 5( 10):el 3391
  • proteins and peptides can be polymerized by cysteine oxidation induced disulfide cross linking.
  • Another aspect of the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising the polymerized product of the invention and a
  • compositions may contain a single homopolymer of an ⁇ protein or peptide, a-synuclein protein or peptide, tau protein or peptide, TDP-43 protein or peptide, amylin protein or peptide, or prion protein or peptide.
  • pharmaceutical composition may contain a mixture of one or more proteins or peptides, i.e. heteropolymers of the one or more aforementioned proteins and/or peptides.
  • composition of the present invention can further contain, in addition to peptide polymers, other pharmaceutically acceptable components ⁇ see REMINGTON'S PHARMACEUTICAL SCIENCE ( 19th ed., 1995), which is hereby incorporated by reference in its entirety).
  • REMINGTON'S PHARMACEUTICAL SCIENCE 19th ed., 1995
  • the pharmaceutical composition will include a pharmaceutically- acceptable, non-toxic carrier or diluent, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration.
  • diluent is selected so as not to affect the biological activity of the composition.
  • Exemplary carriers or diluents include distilled water, physiological phosphate- buffered saline, Ringer's solutions, dextrose solution, and Hank's solution.
  • compositions can also include large, slowly
  • metabolized macromolecules such as proteins, polysaccharides such as chitosan, polylactic acids, polyglycolic acids and copolymers (such as latex functionalized sepharose, agarose, cellulose), polymeric amino acids, amino acid copolymers, and lipid aggregates (such as oil droplets or liposomes).
  • composition of the present invention can further comprise
  • adjuvants contain an adjuvant.
  • One class of preferred adjuvants is aluminum salts, such as aluminum hydroxide, aluminum phosphate, or aluminum sulfate.
  • Such adjuvants can be used with or without other specific immunostimulating agents such as MPL or 3- DMP, QS-21 , flagellin, attenuated Salmonella (e.g., Salmonella typhimitrium), polymeric or monomeric amino acids such as polyglutamic acid or polylysine, or pluronic polyols.
  • Oil-in-water emulsion formulations are also suitable adjuvants that can be used with or without other specific immunostimulating agents such as muramyl peptides (e.g., N-acetylmuramyl-L-threonyl-D-isoglutamine (thr-MDP), N- acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl- D-isoglutaminyl-L-alanine-2-( 1 '-2'dipalmitoyl-sn- -glycero-3- hydroxyphosphoryloxy)-ethylamine (MTP-PE), N-acetylglucsaminyl-N- acetylmuramyl-L-Al-D-isoglu-L-Ala-dipalmitoxy propylamide (DTP-DPP)
  • a suitable oil-in-water emulsion is MF59 (containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE) formulated into submicron particles using a microfluidizer such as Model 1 10Y microfluidizer (Microfluidics, Newton MA) as described in WO90/ 14837 to Van Nest et al., which is hereby incorporated by reference in its entirety.
  • a microfluidizer such as Model 1 10Y microfluidizer (Microfluidics, Newton MA) as described in WO90/ 14837 to Van Nest et al., which is hereby incorporated by reference in its entirety.
  • suitable oil-in-water emulsions include SAF (containing 10% Squalene, 0.4% Tween 80, 5% pluronic-blocked polymer LI 21 , and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion) and Ribi " adjuvant system (RAS; containing 2% squalene, 0.2% Tween 80, and one or more bacterial cell wall components).
  • Ribi " adjuvant system Ribi " adjuvant system
  • Another class of preferred adjuvants is saponin adjuvants, such as Stimulon' M (QS-21 ) or particles generated therefrom such as ISCOMs
  • IFA incomplete or complete Freund's Adjuvant
  • cytokines such as interleukins (IL-1 , IL-2, and IL- 12
  • M-CSF macrophage colony stimulating factor
  • lysolecithin tumor necrosis factor
  • TNF tumor necrosis factor
  • liposome polycation DNA particles Such adjuvants are generally available from commercial sources.
  • the pharmaceutical composition further includes a delivery vehicle.
  • Suitable delivery vehicles include, but are not limited to biodegradable microspheres, microparticles, nanoparticles, liposomes, collagen minipellets, and cochleates.
  • the pharmaceutical agent includes a mucosal delivery system.
  • a preferred mucosal delivery system consists of attenuated Salmonella (e.g., Salmonella typhimurium) with a non-toxic fragment C of tetanus toxin (TetC) or glutathione 5-transferase (GST). Methods of mucosal vaccination via oral administration of 5.
  • Another aspect of the present invention relates to a method of inducing an immune response against an amyloidogenic form of a protein or peptide in a subject.
  • This method involves administering to the subject a polymerized product of the present invention under conditions effective to induce an immune response against the amyloidogenic form of the protein or peptide in the subject.
  • a subject that would benefit from an immune response against an amyloidogenic form of a protein or peptide is selected prior to administering the polymerized product.
  • Amyloidogenic form of a protein are used interchangeably to encompasses any insoluble fibrous protein/peptide aggregate that is deposited intra- or extracellularly within the body. Amyloidogenic protein/peptide deposition may be organ-specific (e.g., central nervous system, pancreas, etc.) or systemic.
  • amyloidogenic proteins/peptides subject to deposition include beta protein precursor, prion and prion proteins, oc-synuclein, tau, ABri precursor protein, ADan precursor protein, amylin, apolipoprotein AI, apolipoprotein All, lyzozyme, cystatin C, gelsolin, protein, atrial natriuretic factor, calcitonin, keratoepithelin, lactoferrin, immunoglobulin light chains, transthyretin, A
  • amyloidosis amyloidosis, p2-microglobulin, immunoglobulin heavy chains, fibrinogen alpha chains, prolactin, keratin, and medin.
  • Amyloid deposition may occur as its own entity or as a result of another illness (e.g. , multiple myeloma, chronic infection, or chronic inflammatory disease).
  • an immune response is the development of a beneficial humoral (antibody mediated) and/or a cellular (mediated by antigen-specific T cells or their secretion products) response directed against the polymerized, non-fibrillogenic proteins or peptides of the polymerized product and cross-reactive with any amyloidogenic protein.
  • a beneficial humoral (antibody mediated) and/or a cellular (mediated by antigen-specific T cells or their secretion products) response directed against the polymerized, non-fibrillogenic proteins or peptides of the polymerized product and cross-reactive with any amyloidogenic protein.
  • Such a response is an active response induced by administration of the immunogenic polymerized protein and/or peptides and represents a therapeutic means for clearing or removing amyloid protein deposits from the body of the subject.
  • the presence of a humoral immunological response can be determined and monitored by testing a biological sample (e.g., blood, plasma, serum, urine, saliva feces, CSF or lymph fluid) from the subject for the presence of antibodies directed to the immunogenic component of the administered polymerized product.
  • a biological sample e.g., blood, plasma, serum, urine, saliva feces, CSF or lymph fluid
  • Methods for detecting antibodies in a biological sample are well known in the art, e.g., ELISA, Dot blots, SDS-PAGE gels or ELISPOT.
  • the presence of a cell-mediated immunological response can be determined by proliferation assays (CD4 + T cells) or CTL (cytotoxic T lymphocyte) assays which are readily known in the art.
  • the present invention is further directed to a method of preventing and/or treating a condition mediated by an amyloidogenic protein or peptide in a subject.
  • This method involves administering to the subject, a polymerized product of the present invention containing one or more polymers or co-polymers comprising an amyloid-beta ( ⁇ ) peptide, an a-synuclein protein or peptide, a tau protein or peptide, a TAR DNA-binding protein 43 (TDP-43) protein or peptide, an amylin protein or peptide, a prion protein (PrP) or peptide or any combination thereof as described supra.
  • ⁇ amyloid-beta
  • TrP prion protein
  • the polymerized product is administered under conditions effective to treat the condition mediated by the amyloidogenic protein or peptide in the subject.
  • a subject at risk of having or having a condition mediated by an amyloidogenic protein or peptide is selected prior to administering the polymerized product of the present invention.
  • Conditions or diseases associated with, or resulting from, the deposition of amyloidogenic proteins or peptides include, but are not limited to, Alzheimer's disease, diffuse Lewy body disease, Down's syndrome, fronto-temporal dementia, Parkinson's disease, hereditary cerebral hemorrhage with amyloidosis, kuru, Creutzfeldt- Jakob disease, Gerstmann-Straussler-Scheinker disease, fatal familial insomnia, British familial dementia, Danish familial dementia, familial corneal amyloidosis, Familial corneal dystrophies, medullary thyroid carcinoma, insulinoma, type 2 diabetes, isolated atrial amyloidosis, pituitary amyloidosis, aortic amyloidosis, plasma cell disorders, familial amyloidosis, senile cardiac amyloidosis, inflammation-associated amyloidosis, familial Mediterranean fever, dialysis- associated amyloidosis, systemic amyloidos
  • polymerized product is effective to stimulate an immune response in the subject that is effective at reducing and/or clearing the amyloidogenic protein that is causing or exacerbating the aforementioned disease conditions.
  • a second aspect of the present invention is directed to an isolated antibody or binding portion thereof having antigenic specificity for an epitope a non- amyloidogenic, non- fibril logenic polymerized product of the present invention.
  • the polymerized product of the present invention comprises two or more protein or peptide units, each unit independently selected from the group consisting of an amyloid-beta ( ⁇ ) peptide, an a-synuclein protein or peptide, a tau protein or peptide, a TAR DNA-binding protein 43 (TDP-43) protein or peptide, an amylin protein or peptide, a prion protein (PrP) protein or peptide, and any combination thereof.
  • ⁇ amyloid-beta
  • TrP TAR DNA-binding protein 43
  • epitope refers to an antigenic determinant of the one or more polymerized proteins or peptides of the present invention that is recognized by the isolated antibody.
  • the epitope recognized by the antibody of the present invention may be a linear epitope, i.e. the primary structure of the amino acid sequence of the target proteins or peptides.
  • the linear epitope recognized by the isolated antibody of the present invention does not have amino acid sequence homology to a non-amyloid protein.
  • the epitope recognized by the isolated antibody of the present invention is a non-linear or conformational epitope, i.e. the tertiary or quaternary structure of a polymerized protein or peptide.
  • the non-linear or conformational epitope recognized by the isolated antibody of the present invention is a conformational epitope that is common to or shared with one or more, or all, amyloidogenic proteins. Accordingly, the isolated antibody of the present invention has antigenic specificity for a shared conformational epitope common to all amyloidogenic proteins known in the art.
  • An isolated antibody of the present invention encompasses any immunoglobulin molecule that specifically binds to an epitope of a polymerized product of the present invention.
  • the antibody of the present invention binds specifically to an epitope that is shared by a polymerized product of the present invention and one or more amyloidogenic proteins.
  • antibody is meant to include intact immunoglobulins derived from natural sources or from recombinant sources, as well as immunoreactive portions (i.e., antigen binding portions) of intact immunoglobulins.
  • the antibodies of the present invention may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, intracellular antibodies (“intrabodies”), antibody fragments (e.g. Fv, Fab and F(ab)2), as well as single chain antibodies (scFv), chimeric antibodies, and humanized antibodies (Ed Harlow and David Lane, USING
  • ANTIBODIES A LABORATORY MANUAL (Cold Spring Harbor Laboratory R-ess, 1 99); Houston et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia coli " Proc Natl Acad Sci USA 85:5879-5883 ( 1988); Bird et al, "Single-Chain Antigen-Binding Proteins," Science 242:423-426 ( 1988)).
  • Antibodies of the present invention may also be synthetic antibodies.
  • a synthetic antibody is an antibody which is generated using recombinant DNA technology, such as, for example, an antibody expressed by a bacteriophage.
  • the synthetic antibody is generated by the synthesis of a DNA molecule encoding and expressing the antibody of the invention or the synthesis of an amino acid specifying the antibody, where the DNA or amino acid sequence has been obtained using synthetic DNA or amino acid sequence technology which is available and well known in the art.
  • Methods for monoclonal antibody production may be carried out using the techniques described herein or other well-known in the art ( MONOCLONAL ANTIBODIES - PRODUCTION, ENGINEERING AND CLINICAL APPLICATIONS (Mary A. Ritter and Heather M. Ladyman eds., 1995), which is hereby incorporated by reference in its entirety).
  • the process involves obtaining immune cells (lymphocytes) from the spleen of a mammal which has been previously immunized with the antigen of interest (i.e., a polymerized protein or peptide product of the present invention) either in vivo or in vitro.
  • Exemplary polymerized products comprising one or more ⁇ peptides, a-synuclein proteins or peptides, tau proteins or peptides, TDP-43 proteins or peptides, amylin proteins or peptides, and a prion proteins or peptides are described supra.
  • the antibody-secreting lymphocytes are fused with myeloma cells or transformed cells, which are capable of replicating indefinitely in cell culture, thereby producing an immortal, immunoglobulin-secreting cell line.
  • Fusion with mammalian myeloma cells or other fusion partners capable of replicating indefinitely in cell culture is achieved by standard and well-known techniques, for example, by using polyethylene glycol (PEG) or other fusing agents (Milstein and Kohler, "Derivation of Specific Antibody-Producing Tissue Culture and Tumor Lines by Cell Fusion," Eur J Immunol 6:51 1 ( 1976), which is hereby incorporated by reference in its entirety).
  • PEG polyethylene glycol
  • the immortal cell line which may be murine, but may also be derived from cells of other mammalian species, is selected to be deficient in enzymes necessary for the utilization of certain nutrients, to be capable of rapid growth, and have good fusion capability.
  • the resulting fused cells, or hybridomas are cultured, and the resulting colonies screened for the production of the desired monoclonal antibodies. Colonies producing such antibodies are cloned, and grown either in vivo or in vitro to produce large quantities of antibody.
  • monoclonal antibodies can be made using recombinant
  • the polynucleotides encoding a monoclonal antibody are isolated from mature B-cells or hybridoma cells, for example, by RT- PCR using oligonucleotide primers that specifically amplify the genes encoding the heavy and light chains of the antibody.
  • the isolated polynucleotides encoding the heavy and light chains are then cloned into suitable expression vectors, which when transfected into host cells such as E.
  • coli cells simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, and monoclonal antibodies are generated by the host cells.
  • recombinant monoclonal antibodies or fragments thereof of the desired species can be isolated from phage display libraries (McCafferty et al., "Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains," Nature 348:552-554 ( 1990);
  • the polynucleotide(s) encoding a monoclonal antibody can further be modified using recombinant DNA technology to generate alternative antibodies.
  • the constant domains of the light and heavy chains of a mouse monoclonal antibody can be substituted for those regions of a human antibody to generate a chimeric antibody.
  • the constant domains of the light and heavy chains of a mouse monoclonal antibody can be substituted for a non-immunoglobulin polypeptide to generate a fusion antibody.
  • the constant regions are truncated or removed to generate the desired antibody fragment of a monoclonal antibody.
  • site -directed or high-density mutagenesis of the variable region can be used to optimize specificity and affinity of a monoclonal antibody.
  • the monoclonal antibody of the present invention can be a humanized antibody.
  • Humanized antibodies are antibodies that contain minimal sequences from non-human (e.g., murine) antibodies within the variable regions. Such antibodies are used therapeutically to reduce antigenicity and human anti-mouse antibody responses when administered to a human subject. In practice, humanized antibodies are typically human antibodies with minimal to no non-human sequences.
  • An antibody can be humanized by substituting the complementarity determining region (CDR) of a human antibody with that of a non-human antibody (e.g., mouse, rat, rabbit, hamster, etc.) having the desired specificity, affinity, and capability (Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse," Nature 321 :522-525 (1986);
  • CDR complementarity determining region
  • the humanized antibody can be further modified by the substitution of additional residues either in the Fv framework region and/or within the replaced non-human residues to refine and optimize antibody specificity, affinity, and/or capability.
  • the monoclonal ⁇ of the present invention can also be a human monoclonal ⁇ .
  • a human antibody is an antibody produced by a human or an antibody having an amino acid sequence corresponding to an antibody produced by a human.
  • Human antibodies can be produced using various techniques known in the art. Immortalized human B lymphocytes immunized in vitro or isolated from an immunized individual that produce an antibody directed against a target antigen can be generated (See e.g., Reisfeld et al., MONOCLONAL ANTIBODIES AND CANCER THERAPV 77 (Alan R. Liss ed., 1985) and U.S. Patent No.
  • the human antibody can be selected from a phage library, where that phage library expresses human antibodies (Vaughan et al., "Human Antibodies with Sub-Nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library," Nature Biotechnology, 14:309-3 14 2 046941
  • Procedures for raising polyclonal antibodies are also well known in the art. Typically, such antibodies are raised by administering the polymerized product of the present invention subcutaneously to rabbits ⁇ e.g., New Zealand white rabbits), goats, sheep, swine, or donkeys which have been bled to obtain pre-immune serum.
  • the polymerized product can be injected in combination with an adjuvant. The rabbits are bled approximately every two weeks after the first injection and
  • polyclonal antibodies are recovered from the serum by affinity chromatography using the corresponding polymerized product to capture the antibody. This and other procedures for raising polyclonal antibodies are disclosed in Ed Harlow and David Lane, USING ANTIBODIES: A LABORATORY MANUAL (Cold Spring Harbor Laboratory Press, 1988), which is hereby incorporated by reference in its entirety.
  • the present invention encompasses binding portions of such antibodies.
  • binding portions include the monovalent Fab fragments, Fv fragments ⁇ e.g., single-chain antibody, scFv), and single variable VH and Vi, domains, and the bivalent F(ab')2 fragments, Bis-scFv, diabodies, triabodies, minibodies, etc.
  • These antibody fragments can be made by conventional procedures, such as proteolytic fragmentation procedures, as described in James Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE 98- 1 18 (Academic Press, 1983) and Ed Harlow and David Lane, ANTIBODIES: A
  • antibody fragments engineered to bind to intracellular proteins i.e. intrabodies.
  • amyloid protein deposits are generally extracellular, intracellular accumulation of certain amyloid proteins (e.g., ⁇ 1 -42) have been observed (D' Andrea et al., "Targeting Amyloid Beta: Targeting Intracellular ⁇ 42 for Alzheimer's Disease Drug Discover," Drug Development Research 56: 194-200 (2002); Knobloch et al., “Intracellular Abeta and Cognitive Deficits Precede beta-Amyloid Deposition in arcAbeta Mice,” Neurobiol Aging 28(9).T 297-306 (2007), which are hereby incorporated by reference in their entirety).
  • an intrabody can be used to bind selectively to an epitope of an amyloid protein within a cell.
  • the intrabody recognizes an epitope of the ⁇ 1 -42 oligomer accumulating within the perikaryon of affected neurons (e.g., pyramidal neurons) in AD.
  • Intrabodies are generally obtained by selecting a single variable domain from variable regions of an antibody having two variable domains (i.e., a heterodimer of a heavy chain variable domain and a light chain variable domain).
  • Single chain Fv fragments, Fab fragments, ScFv-Ck fusion proteins, single chain diabodies, V H -CH1 fragments, and even whole IgG molecules are suitable formats for intrabody development (Kontermann R.E., "Intrabodies as Therapeutic Agents," Methods 34: 163-70 (2004), which is here by incorporated by reference in its entirety).
  • Intrabodies having antigen specificity for a conformational epitope of an amyloidogenic protein can be obtained from phage display, yeast surface display, or ribosome surface display. Methods for producing libraries of intrabodies and isolating intrabodies of interest are further described in U.S. Published Patent Application No. 20030104402 to Zauderer and U.S. Published Patent Application No. 20050276800 to Rabbitts, which are hereby incorporated by reference in their entirety.
  • Antibody mimics are also suitable for use in accordance with the present invention.
  • a number of antibody mimics are known in the art including, without limitation, those known as monobodies, which are derived from the tenth human fibronectin type III domain ( l0 Fn3) ( oide et al., "The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins," J Mol Biol 284: 1 141-1 151 (1998); Koide et al., "Probing Protein Conformational Changes in Living Cells by Using Designer Binding Proteins: Application to the Estrogen Receptor," Proc Natl Acad Sci USA 99: 1253-1258 (2002), each of which is hereby incorporated by reference in its entirety); and those known as affibodies, which are derived from the stable alpha-helical bacterial receptor domain Z of staphylococcal protein A (Nord et al., "Binding Proteins Selected from Combinatorial Libraries of an alpha-
  • the present invention is further directed to a pharmaceutical composition containing the isolated antibody of the present invention as described supra.
  • the isolated antibody recognizes and binds to a shared conformational epitope common to one or more amyloid proteins.
  • the pharmaceutical composition of the present invention may contain an antibody mixture where all antibodies recognize the same conformational epitope.
  • the pharmaceutical composition may contain an antibody mixture where one or more antibodies recognize one or more different conformational epitopes of amyloid proteins.
  • the pharmaceutical composition of the present invention further contains a pharmaceutically acceptable carrier or other pharmaceutically acceptable components as described supra.
  • Another aspect of the present invention relates to a method of treating a condition mediated by an amyloidogenic protein in a subject.
  • This method involves administering to the subject an antibody of the present invention, where the antibody has antigen specificity for an epitope of a non-amyloidogenic, non-fibrillogenic polymerized product, wherein the polymerized product comprises two or more protein and or peptide units, each unit independently selected from the group consisting of an amyloid-beta ( ⁇ ) peptide, an a-synuclein protein or peptide, a tau protein or peptide, a TAR DNA-binding protein 43 (TDP-43) protein or peptide, an amylin protein or peptide, a prion protein (PrP) protein or peptide, and any combination thereof.
  • ⁇ amyloid-beta
  • TrP TAR DNA-binding protein 43
  • the antibody has antigen specificity for a shared conformational epitope that is common to one or more amyloidogenic proteins.
  • the antibody or a pharmaceutical composition containing the antibody is administered in an amount effective to treat the condition involving the amyloidogenic protein in the subject.
  • the antibody or pharmaceutical composition containing the antibody is administered in an amount effective to generate passive immunity in the subject against one or more amyloidogenic proteins, thereby facilitating the clearance of amyloid deposits from the subject.
  • a subject having a condition or at risk of developing a condition mediated by an amyloidogenic protein is selected prior to administration of the antibody of the present invention.
  • Subjects amenable to treatment in accordance with the methods of the present invention include individuals at risk of developing an amyloid related disease but not showing symptoms, as well as subjects showing symptoms at the time of therapeutic intervention (i.e. antibody administration).
  • Diseases subject to treatment include any disease associated with or caused by an amyloidogenic protein as described supra.
  • the pharmaceutical compositions of the present invention contain polymerized products that are not endogenous to the body, or antibodies specific for only pathological protein conformations.
  • compositions of the present invention can be administered prophylactically to the general population without the need for any assessment of the risk of the subject patient.
  • present methods and compositions are especially suitable for prophylactic treatment of individuals who have a known genetic risk of Alzheimer's disease or other condition related to an amyloidogenic protein.
  • Genetic markers associated with a risk of Alzheimer's disease include mutations in the APP gene, particularly mutations at position 717 and positions 670 and 671 referred to as the Hardy and Swedish mutations respectively.
  • Other markers of risk are mutations in the presenilin genes, PS 1 and PS2, and mutations in ApoE4, family history of AD, hypercholesterolemia, or atherosclerosis.
  • treatment can begin at any age (e.g., 10, 20,
  • Treatment typically entails multiple dosages over a period of time. Treatment can be monitored by assaying antibody, or activated T-cell or B-cell responses to the therapeutic agent (e.g., polymerized product) over time. If the response falls, a booster dosage is indicated. In the case of potential Down's syndrome patients, treatment can begin antenatally by administering the therapeutic agent to the mother or shortly after birth.
  • therapeutic agent e.g., polymerized product
  • the pharmaceutical compositions of the present invention are administered to a patient susceptible to, or otherwise at risk of, a particular disease in an amount sufficient to eliminate or reduce the risk or delay the onset of the disease.
  • pharmaceutical compositions are administered to a patient suspected of, or already suffering from an amyloidogenic disease in an amount sufficient to cure, or at least partially arrest, the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as a therapeutically- or pharmaceutically-effective dose.
  • agents are usually administered in several dosages until a sufficient immune response has been achieved. Typically, the immune response is monitored and repeated dosages are given if the immune response starts to fade.
  • compositions of the present invention for the treatment of the above described conditions vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic.
  • the subject is a human, but in some diseases, such as prion protein related diseases, the subject can be a nonhuman mammal, such as a bovine.
  • Other non-human mammals amenable to treatment in accordance with the methods of the present invention include primates, dogs, cats, rodents (e.g. , mouse, rat, guinea pig), horses, deer, cervids, cattle and cows, sheep, and pigs.
  • Treatment dosages need to be titrated to optimize safety and efficacy, and could involve oral treatment.
  • a polymerized product of the present invention containing one or more polymerized or copolymerized ⁇ , ⁇ -synuclein, tau, TDP-43, amylin, and/or PrP protein or peptide immunogens
  • the appropriate dosage will depend on whether adjuvant is coadministered, with higher dosages being required in the absence of adjuvant.
  • the amount of an immunogen for administration sometimes varies from per patient and more usually from 5-50C ⁇ g per injection for human administration.
  • l -2mg per injection typically about 10, 20, 50 or 100 ⁇ g is used for each human injection.
  • the timing of injections can vary significantly from once a day, to once a week, to once a month, to once a year, to once a decade.
  • an effective dosage can be monitored by obtaining a fluid sample from the patient, generally a blood serum sample, and determining the titer of antibody developed against the immunogen, using methods well known in the art and readily adaptable to the specific antigen to be measured.
  • a sample is taken prior to initial dosing and subsequent samples are taken and titered after each immunization.
  • a dose or dosing schedule which provides a detectable titer at least four times greater than control or "background" levels at a serum dilution of 1 : 100 is desirable, where background is defined relative to a control serum or relative to a plate background in ELISA assays.
  • a dosage of immunogen is given, the dosage is greater than ⁇ g/patient and usually greater than 10 ⁇ g/patient if adjuvant is also administered, and greater than l C ⁇ g/patient and usually greater than 1 OO ⁇ ig/patient in the absence of adjuvant.
  • a typical regimen consists of an immunization followed by booster injections at 6 weekly intervals.
  • Another regimen consists of an
  • booster injections 1 , 2 and 12 months later Another regimen entails an injection every two months for life.
  • booster injections can be on an irregular basis as indicated by monitoring of immune response.
  • the dosage ranges from about 0.0001 to 100 mg/kg, and more usually 0.01 to 5 mg kg of the host body weight.
  • An exemplary treatment regime entails administration once per every two weeks or once a month or once every 3 to 6 months.
  • two or more monoclonal antibodies with different binding specificities are administered simultaneously, in which case the dosage of each antibody administered falls within the ranges indicated.
  • Antibody is usually administered on multiple occasions. Intervals between single dosages can be weekly, monthly or yearly. Intervals can also be irregular as indicated by measuring blood levels of antibody to polymerized proteins or peptide in the patient.
  • antibody can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the antibody in the patient. In general, human antibodies show the longest half life, followed by humanized antibodies, chimeric antibodies, and nonhuman antibodies. The dosage and frequency of administration can vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, a relatively low dosage is administered at relatively infrequent intervals over a long period of time. Some patients continue to receive treatment for the rest of their lives. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably until the patient shows partial or complete amelioration of symptoms of disease. Thereafter, the patient can be administered a prophylactic regime.
  • compositions of the present invention i.e., polymerized products and antibodies, can be administered by parenteral, topical, intravenous, oral,
  • subcutaneous, intraperitoneal, intranasal or intramuscular means for prophylactic and/or therapeutic treatment The most typical route of administration for compositions formulated to induce an immune response is subcutaneous although others can be equally effective. The next most common is intramuscular injection. This type of injection is most typically performed in the arm or leg muscles.
  • Intravenous injections as well as intraperitoneal injections, intra-arterial, intracranial, or intradermal injections are also effective in generating an immune response.
  • agents such as antibodies are injected directly into a particular tissue where deposits have accumulated, for example intracranial injection.
  • Intramuscular injection or intravenous infusion are preferred for administration of antibody.
  • particular therapeutic antibodies are injected directly into the cranium.
  • antibodies are administered as a sustained release composition or device, such as a Medipad"" device.
  • the pharmaceutical agents of the present invention may be formulated for parenteral administration. Solutions or suspensions of the agent can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils.
  • oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil.
  • water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions.
  • these preparations contain a preservative to prevent the growth of microorganisms.
  • compositions suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
  • compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • Intraperitoneal or intrathecal administration of the agents of the present invention can also be achieved using infusion pump devices such as those described by Medtronic, Northridge, CA. Such devices allow continuous infusion of desired compounds avoiding multiple injections and multiple manipulations.
  • compositions of the present invention may also be formulated as a depot preparation.
  • Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • Another aspect of the present invention relates to a method of diagnosing an amyloid disease in a subject.
  • This method involves detecting, in the subject, the presence of an amyloidogenic proteins or peptides using a diagnostic reagent, where the diagnostic reagent is an antibody, or active binding fragment thereof, of the present invention.
  • the antibody has antigenic specificity for a conformational epitope of an amyloidogenic form of a protein.
  • the conformational epitope recognized by the antibody is shared with one or more other amyloidogenic protein or peptides.
  • the diagnosis of the amyloid disease is based on the detection of an amyloidogenic protein or peptide in the subject.
  • Detecting the presence of amyloidogenic deposits in a subject using the diagnostic reagent can be achieved by obtaining a biological sample from the subject (e.g., blood, urine, cerebral spinal fluid), contacting the biological sample with the diagnostic antibody reagent, and detecting binding of the diagnostic antibody reagent to an amyloidogenic protein in the sample from the subject.
  • a biological sample from the subject e.g., blood, urine, cerebral spinal fluid
  • Assays for carrying out the detection of an amyloid protein in a biological sample using a diagnostic antibody are well known in the art and include, without limitation, ELISA,
  • detecting the presence of amyloid deposits in a subject using diagnostic antibody reagent of the present invention can be achieved using in vivo imaging techniques.
  • In vivo imaging involves administering to the subject the diagnostic antibody having antigenic specificity for a conformational epitope of a polymerized product containing two or more protein and/or peptide units where each unit is independently selected from the group consisting of ⁇ , ⁇ -synuclein, tau, TDP- 43, amylin, and/or PrP proteins or peptides, and detecting the binding of the diagnostic agent to the amyloidogenic protein in vivo.
  • preferred antibodies bind to a conformational epitope of an amyloidogenic form of a protein or peptide without binding to the non-amyloidogenic proteins and without binding to the non-pathological forms of the amyloidogenic proteins.
  • Diagnostic antibodies or similar reagents can be administered by intravenous injection into the body of the patient, or directly into the brain by intracranial injection or by drilling a hole through the skull.
  • the dosage of antibody should be within the same ranges as for treatment methods.
  • the antibody is labeled, although in some methods, the primary antibody with affinity for the conformational epitope of an amyloid protein is unlabelled and a secondary labeling agent is used to bind to the primary antibody.
  • the choice of label depends on the means of detection. For example, a fluorescent label is suitable for optical detection. Use of paramagnetic labels is suitable for tomographic detection without surgical intervention. Radioactive labels can also be detected using PET or SPECT.
  • Diagnosis is performed by comparing the number, size, and/or intensity of labeled amyloid protein deposits in a sample from the subject or in the subject, to corresponding baseline values.
  • An appropriate baseline value can be the average level of amyloid protein deposition in a population of undiseased individuals. Alternatively, an appropriate baseline value may be the level of amyloid protein deposition in the same subject determined at an earlier time.
  • the diagnostic methods described above can also be used to monitor a subject's response to therapy.
  • detection of amyloid deposits in the subject is determined prior to the commencement of treatment.
  • the level of amyloid deposition in the subject at this timepoint is used as a baseline value.
  • the detection of amyloid deposits can be repeated, and the measured values thereafter compared with the baseline values. A decrease in values relative to baseline signals a positive response to treatment.
  • kits for performing the above described diagnostic and monitoring methods.
  • a diagnostic antibody reagent preferably the antibody of the present invention that has antigenic specificity for a polymerized ⁇ , ⁇ -synuclein, tau, TDP-43, amylin, and/or PrP protein or peptide product.
  • the kit can also include a detectable label.
  • the diagnostic antibody itself may contain the detectable label (e.g., fluorescent molecule, biotin, etc.) which is directly detectable or detectable via a secondary reaction (e.g., reaction with strepavidin).
  • a second reagent containing the detectable label may be utilized, where the second reagent has binding specificity for the primary antibody.
  • the antibodies of the kit may be supplied prebound to a solid phase, such as to the wells of a microtiter dish.
  • Diagnostic kits of the present invention also include kits that are useful for detecting antibody production in a subject following administration of a polymerized protein or peptide of the present invention.
  • kits include a reagent that contains the antigenic epitope of the antibodies generated by the subject in a polymerized product as described supra.
  • the kit also includes a detectable label, in a preferred embodiment, the label is typically in the form of labeled anti-idiotypic antibodies.
  • the antigenic epitope reagents of the kit can be supplied prebound to a solid phase, such as to the wells of a microtiter dish.
  • ABri peptide (Cys-Ser-Arg-Thr-Val-Lys-Lys-Asn-Ile-Ile-Glu-Glu-Asn) (SEQ ID N0:8), and ⁇ 1 -30 ⁇ 18 ⁇ 19 (daefrhdsgy evhhqklkkf aedvgsnkga) (SEQ ID NO: 12) were synthesized on an ABI 430A peptide synthesizer (AME Bioscience, Chicago, IL) at the Keck peptide synthesis facility at Yale University, CT, using a Vydac C I 8 preparative column, 2.5 x 30 cm (Vydac Separations, Hesperia, CA).
  • Tg mice transgenic mice were used in these experiments.
  • the second model develops extensive congophilic angiopathy (CAA) (Davis et al., "Early-Onset and Robust Cerebral Microvascular Accumulation of Amyloid Beta-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid Beta-Protein Precursor," /. Biol. Chem. 279:20296-306 (2004), which is hereby incorporated by reference in its entirety).
  • CAA congophilic angiopathy
  • mice were immunized 4 times biweekly, subcutaneously with 50 ⁇ g/animal of polymerized peptide in sterile saline:Alum 9: 1, and thereafter 4 times bimonthly with 25 igjm ⁇ ma ⁇ until the 12 month.
  • mice were subject to locomotor and cognitive behavioral testing (radial arm maze), followed by histological and biochemical analysis. Animals were bled from the caudal vein prior to inoculation (TO), after the 6 th inoculation (T6) and at the time of sacrifice (TF). The blood was collected in heparinized tubes and plasma separated and stored at -80°C.
  • a Hamilton-Kinder Smart-frame Photobeam System was used to make a
  • Exploratory locomotor activity is recorded in a circular open field activity chamber measuring (70 x 70 cm).
  • a video camera mounted above the chamber automatically recorded horizontal movements in the open field in each dimension ⁇ i.e., x, y, and two z planes).
  • Total distance was measured in centimeters (cm) traveled and is defined as sequential movement interruptions of the animal measured relative to the background. The duration of the behavior was timed for 15 min. Results were reported based on distance traveled (cm), mean resting time, and maximum velocity of the animal.
  • Antibody Levels were determined in duplicate on
  • Alzheimer's Model Mice Eur. J. Neurosci. 24:2530-2542 (2006), which are hereby incorporated by reference in their entirety), in which 5 ⁇ / ⁇ ⁇ 1-40, ⁇ 1-42, ⁇ -30 ⁇ , or pABri was coated onto Immulon 2HB 96 well microtiter wells (Thermo, Waltham, MA).
  • the bound antibodies were detected by a horseradish peroxidase labeled goat anti-mouse IgG (Amersham Biosciences, Piscataway, NJ) or a peroxidase conjugated goat anti-mouse IgM (Sigma; A8786).
  • Tetramethyl benzidine TMB; Pierce, Rockford, IL was the color developing substrate and the readings were done at 450nm.
  • mice were anesthetized with sodium pentobarbital ( 150 mg/kg, i.p.), perfused transaortically with phosphate buffer, and the brains processed as described previously (Asuni et al., " ⁇ Derivative Vaccination in Alum Adjuvant Prevents Amyloid Deposition and Does Not Cause Brain Microhemorrhages in Alzheimer's Model Mice," Eur. J. Neurosci. 24:2530-2542 (2006); NASAdsson et al., "An Attenuated Immune Response is Sufficient to Enhance Cognition in an
  • Alzheimer's Disease Mouse Model Immunized With Amyloid- ⁇ Derivatives /.
  • IgM titers were noted against ⁇ 1-42 and polymerized ABri at Tl and Tf (Figure 5A). Significant IgM titers against ⁇ 1-40 were observed at Tl , and significant IgG titers against ⁇ 1 -40 were observed at Tf in these animals. In the polymerized ⁇ ⁇ - 30Ki 8 K
  • Tg3x animals administered polymerized ABri (Tg-pABri), polymerized ⁇ ⁇ - 30] 8 Ki9K (Tg-AB 1-30KK), or the combination of polymerized peptides (Tg- combined) compared to transgenic control (Tg-control) animals as shown in Figure 6A.
  • Tg-control transgenic control
  • FIG. 6B There was also a significant reduction in PHFl in the hippocampus
  • Figure 6C cortex
  • No significant difference in PHFl burden in the hippocampus or cortex was found between Tg- control and Tg- ⁇ 1-30 ⁇ 8 ⁇ ⁇ 9 ⁇ treated animals.
  • polymeric synthetic peptides have been designed that mimic the secondary structure found in amyloid and oligomeric forms of ⁇ and pathological forms of tau.
  • the antibody response elicited can target both amyloid and tau pathology resulting in a cognitive benefit, pathology burden reduction, and lack of apparent autoimmune toxicity.
  • PrP peptides and recombinant protein were subject to controlled polymerization as described herein and Goni et al, "Immunomodulation Targeting Abnorraal Protein Conformation Reduces Pathology in a Mouse Model of
  • Figures 9 and 10 show the anti-PrP IgA antibody titers in feces and anti-PrP IgM antibody titers in plasma, respectively, in both control and vaccinated deer over the course of the treatment regimen described above.
  • the control group did not develop any noticeable IgA titer whereas the vaccinated group showed some increase in mucosa titer after the immune response was established with the salmonella oral delivery.
  • the IgA titers were initially very low (T5) but were greatly enhanced after the animals were boosted with the polymerized PrP and PrP fragments (T6 and T7) showing the importance of these antigenic preparation on generating a sustainable immune response (Figure 9).
  • the control group did not show any noticeable increase in antibody titer; whereas the vaccinated group showed some concomitant IgM titer in serum at the same time of the mucosal response (T5).
  • Anti-PrP antibody titers in the vaccinated animals greatly increased after the two boosts with the polymerized PrP and PrP fragments showing that this type of boost could invoke a therapeutic serum response.
  • FIG. 10 contains immunoblot data using purified antibodies from T7 in vaccinated animal 781 and control animal 786.
  • Lane 1 of the blot contains salmonella lysate, to which antibodies in both animals were highly reactive to.
  • Lanes 4 and 5 contain deer PrP and polymerized deer PrP.
  • the bands appearing in both lanes of the blot incubated with antibodies from the vaccinated animal but not in the lanes of the blot incubated with antibodies from the control animal indicate the generation and presence of deer PrP antibodies in the vaccinated, but not control animals.
  • Lanes 2 and 3 contain sheep PrP and polymerized sheep PrP. The absence of bands in these lanes indicates the specificity of the antibody response observed in the vaccinated animals, i.e., the generated antibodies are specific for deer PrP.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)

Abstract

La présente invention concerne des produits et des compositions polymérisés qui s'avèrent être utiles pour le traitement et la prévention d'une maladie amyloïde chez un sujet. L'invention concerne en outre des anticorps isolés qui reconnaissent un épitope conformationnel commun des protéines ou des peptides amyloïdogènes qui sont utiles pour le diagnostic, le traitement et la prévention d'une maladie amyloïde.
PCT/US2012/046941 2011-07-19 2012-07-16 Modulation immunothérapeutique de maladie amyloïdogène à l'aide de protéines et peptides polymérisés non fibrillogènes, non amyloïdogènes WO2013012811A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161509442P 2011-07-19 2011-07-19
US201161509320P 2011-07-19 2011-07-19
US61/509,442 2011-07-19
US61/509,320 2011-07-19

Publications (2)

Publication Number Publication Date
WO2013012811A2 true WO2013012811A2 (fr) 2013-01-24
WO2013012811A3 WO2013012811A3 (fr) 2013-04-11

Family

ID=47555898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/046941 WO2013012811A2 (fr) 2011-07-19 2012-07-16 Modulation immunothérapeutique de maladie amyloïdogène à l'aide de protéines et peptides polymérisés non fibrillogènes, non amyloïdogènes

Country Status (2)

Country Link
US (3) US9926353B2 (fr)
WO (1) WO2013012811A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572894B1 (fr) * 2001-11-21 2016-04-13 New York University Polypeptides immunogènes synthétiques ne formant pas de dépôts et peptides homologues déstinés à des répétitions amyloide beta, protéine prion, amyline, alpha-synucléine, ou polyglutamine pour induction d'une réponse immunitaire à ceux-ci
WO2013012811A2 (fr) 2011-07-19 2013-01-24 New York University Modulation immunothérapeutique de maladie amyloïdogène à l'aide de protéines et peptides polymérisés non fibrillogènes, non amyloïdogènes
US8906382B2 (en) 2011-07-19 2014-12-09 New York University Method for treating amyloid disease
CN108623682A (zh) 2012-07-03 2018-10-09 华盛顿大学 针对tau的抗体
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
EP3440094B1 (fr) * 2016-04-07 2021-02-17 Case Western Reserve University Inhibiteur de la localisation mitochondriale de tdp -43 pour le traitement d'une maladie neurodégénérative
CA3051839A1 (fr) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Anticorps anti-alpha-synucleine et leurs utilisations
WO2023245063A2 (fr) * 2022-06-14 2023-12-21 The Johns Hopkins University Identification de néo-épitopes codés par un exon cryptique tdp-43 en tant que biomarqueurs de fluide fonctionnel pour la maladie d'alzheimer et la démence associée

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050383A1 (en) * 2006-03-29 2008-02-28 New York University Immunotherapy for clearing pathological tau conformers
US20090163420A1 (en) * 2001-11-21 2009-06-25 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or polyglutamine repeats for induction of an immune response thereto
WO2010016912A2 (fr) * 2008-08-07 2010-02-11 Mercia Pharma, Llc Compositions immunothérapeutiques pour le traitement de la maladie d'alzheimer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180562A (en) 1973-05-08 1979-12-25 Northwestern University Glutaraldehyde polymerized ragweed antigen E preparation for treatment of allergic patients sensitive to ragweed pollen
JPH0832637B2 (ja) 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
AU4376093A (en) 1992-05-15 1993-12-13 Instituto Nazionale Neurologico C. Besta Soluble prion polypeptides, and methods for detecting and purifying thereof
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
CA2191101C (fr) 1994-05-25 2001-08-07 Ellis L. Kline Compositions et procedes de traitement de maladies a formation de plaque
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
AU4749297A (en) 1996-10-08 1998-05-05 University Of Washington Therapeutic and diagnostic applications of laminin and laminin-derived protein fragments
US6022859A (en) 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
AU6689698A (en) 1997-03-06 1998-09-22 University Of Washington Methods for producing pure perlecan and other heparan sulfate proteoglycans
GB9719879D0 (en) 1997-09-19 1997-11-19 Neuropa Ltd Protein
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
ES2253839T3 (es) 1997-12-03 2006-06-01 Neuralab, Ltd. Supresion de cambios relacionados con amiloide beta en la enfermedad de alzheimer.
US6274615B1 (en) 1998-03-25 2001-08-14 South Alabama Medical Science Foundation Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2000071671A2 (fr) 1999-05-26 2000-11-30 New York University Nouveaux genes mutants dans la demence familiale britannique et la demence familiale danoise
WO2000072800A2 (fr) 1999-05-28 2000-12-07 Smithkline Beecham Corporation Antagonistes du recepteur d'il-8
CA2408925A1 (fr) 2000-05-22 2001-11-29 New York University Peptides immunogenes synthetiques mais non-amyloidogenes homologues de beta-amyloide, destines a induire une reaction immunitaire contre les peptides beta-amyloide et les depots amyloides
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
WO2002011669A2 (fr) 2000-08-07 2002-02-14 Antigenics, Llc Compositions comprenant des proteines de choc thermique ou alpha(2)macroglobulines, des molecules antigeniques et des saponines, et procedes d'utilisation associes
WO2003044051A1 (fr) 2001-11-20 2003-05-30 Atgen Co., Ltd. Nouveaux peptides conferant une resistance au stress environnemental et proteines de fusion contenant lesdits peptides
AU2002366355A1 (en) 2001-12-17 2003-06-30 New York State Office Of Mental Health SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
US20030219853A1 (en) * 2002-03-01 2003-11-27 Szu-Yi Chou Method of cross-linking a compound
WO2004056318A2 (fr) 2002-12-19 2004-07-08 New York University Methode permettant de traiter une maladie amyloide
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7632816B2 (en) 2003-03-28 2009-12-15 New York University Treatment of Alzheimer amyloid deposition
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
US20100298202A1 (en) 2007-07-06 2010-11-25 Mayo Foundation For Medical Education And Research Bri polypeptides and reducing ab aggregation
US20110117100A1 (en) 2008-11-03 2011-05-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosis, stratification and treatment of amyloidogenic diseases
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
WO2013012811A2 (fr) 2011-07-19 2013-01-24 New York University Modulation immunothérapeutique de maladie amyloïdogène à l'aide de protéines et peptides polymérisés non fibrillogènes, non amyloïdogènes
US8906382B2 (en) 2011-07-19 2014-12-09 New York University Method for treating amyloid disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163420A1 (en) * 2001-11-21 2009-06-25 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or polyglutamine repeats for induction of an immune response thereto
US20080050383A1 (en) * 2006-03-29 2008-02-28 New York University Immunotherapy for clearing pathological tau conformers
WO2010016912A2 (fr) * 2008-08-07 2010-02-11 Mercia Pharma, Llc Compositions immunothérapeutiques pour le traitement de la maladie d'alzheimer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SADLER, K. ET AL.: 'Synthetic peptide epitope-based polymers: controlling size and determining the efficiency of epitope incorporation' J. PEPT. RES. vol. 60, no. 3, September 2002, pages 150 - 158 *

Also Published As

Publication number Publication date
US20230130218A1 (en) 2023-04-27
WO2013012811A3 (fr) 2013-04-11
US20190338004A1 (en) 2019-11-07
US9926353B2 (en) 2018-03-27
US11332506B2 (en) 2022-05-17
US20130022544A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
US20230130218A1 (en) Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US10253070B2 (en) Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
JP7229980B2 (ja) 病理学的タウタンパク質の免疫学的標的化方法
US7772375B2 (en) Monoclonal antibodies that recognize epitopes of amyloid-beta
KR100767146B1 (ko) Ａβ 펩티드를 격리시키는 인간화 항체
RU2523894C2 (ru) Предупреждение и лечение церебральной амилоидной ангиопатии
CA2633399C (fr) Vaccin therapeutique
ES2396555T3 (es) Anticuerpos que reconocen péptido beta amiloide
US20060153772A1 (en) Contextual fear conditioning for predicting immunotherapeutic efficacy
US20110250217A1 (en) Methods and compositions for eliciting an amyloid-selective immune response
TW200906852A (en) Monoclonal antibody
KR20030066695A (ko) 베타 아밀로이드 펩티드를 인식하는 인간화된 항체
JP2008524247A (ja) 認知の改善における使用のためのアミロイドβ抗体
US20180148499A1 (en) Antibody Therapy for Amyloid Beta Disease
CN101325972B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体
JP2007522119A (ja) アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
AU2012244075B2 (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12815324

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 19/05/2014)

122 Ep: pct application non-entry in european phase

Ref document number: 12815324

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载